Dr. Juan Miguel Cejalvo Andújar

Emerging Investigator
Research Group on Breast Cancer Biology

Presentation


Dr. Cejalvo was trained as a Medical Oncologist at the Hospital Clínico of Valencia being supervised by Prof. Andrés Cervantes and Prof. Ana Lluch in 2014. He is doctor in Biomedicine at the University of Barcelona and doctor in Medicine at the University of Valencia (Extraordinary PhD Award-2020). He was awarded with a PhD4MD programme at IDIBAPD and IRB Barcelona supervised by Dr. Aleix Prat and Dr. Roger Gomis. During this period was an excellent opportunity to complement his training as a translational researcher. He studied the metastatic process and dormant cells in breast cancer and used modern techniques sucha as CRIPR-CAS9, shRNA, advanced digital microscopy and developed in vivo experiments. He described for the first time the molecular subtype of breast cancer distribution between primary and metastatic tumor.

He returned to Valencia in 2019 with a Rio Hortega-SEOM contract. He was integrated into the Breast Cancer Unit and was involved in clinical trials as principal investigator. Moreover, he is the coordinator of the translational research and lead the breast cancer laboratory. He did a Masters’ Degree in Molecular Oncology in the CNIO and Expert Coruse in Immunology at the University of Navarra.

Finally, he is a postdoctoral Joan Rodes researcher and participates as principal investigator of different projects that have been financed by competitive funding. He collaborates as a teacher in the Master de Senologia at the Univertisty of Barcelona since 2019 and is an Executive Board Member of SOLTI since may-23.

Emerging
Investigator
Dr. Juan Miguel Cejalvo Andújar

juanmitch5@hotmail.com

Publications
NK cell-triggered CCL5/IFNgamma-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer. Santana-Hernandez S, Suarez-Olmos J, Servitja S, Berenguer-Molins P, Costa-Garcia M, Comerma L, Rea A, Perera-Bel J, Menendez S, Arpi O, Bermejo B, Martinez M, Cejalvo J, Comino-Mendez I, Pascual J, Alba E, Lopez-Botet M, Rojo F, Rovira A, Albanell J, Muntasell A. Journal of Experimental & Clinical Cancer Research. 2024 Jan 3;43(1):10. doi: 10.1186/s13046-023-02918-4. PMID: 38167224

Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. Schettini F, Chic N, Brasó-Maristany F, Paré L, Pascual T, Conte B, Martínez-Sáez O, Adamo B, Vidal M, Barnadas E, Fernández-Martinez A, González-Farre B, Sanfeliu E, Cejalvo JM, Perrone G, Sabarese G, Zalfa F, Peg V, Fasani R, Villagrasa P, Gavilá J, Barrios CH, Lluch A, Martín M, Locci M, De Placido S, Prat A. NPJ Breast Cancer. 2023 Apr 29;9(1):32. doi: 10.1038/s41523-023-00538-x. Erratum for: NPJ Breast Cancer. 2021 Jan 4;7(1):1. PMID: 37120452

AXL – a new player in resistance to HER2 blockade. Adam-Artigues A, Arenas E, Arribas J, Prat A, Cejalvo J. Cancer Treatment Reviews. 2023 Dec:121:102639. doi: 10.1016/j.ctrv.2023.102639. PMID: 37864955

Delivery of miR-200c-3p using tumor-targeted mesoporous silica nanoparticles for breast cancer therapy. Garrido-Cano I, Adam-Artigues A, Lameirinhas A, Blandez J, Candela-Noguera V, Lluch A, Bermejo B, Sancenon F, Cejalvo J, Martinez-Manez R, Eroles P. ACS Applied Materials & Interfaces. 2023 Aug 16;15(32):38323-38334. doi: 10.1021/acsami.3c07541. PMID: 37549382

High VEGFR3 expression reduces doxorubicin efficacy in triple-negative breast cancer. Torres Ruiz S, Tormo E, Garrido Cano I, Lameirinhas A, Rojo F, Madoz Gurpide J, Burgues O, Hernando C, Bermejo B, Martinez MT, Lluch A, Cejalvo JM, Eroles P. International Journal of Molecular Sciences. 2023 Feb 10;24(4):3601. doi: 10.3390/ijms24043601. PMID: 36835014

HOPE (SOLTI-1903) breast cancer study: real-world, patient-centric, clinical practice study to assess the impact of genomic data on next treatment decision-choice in patients with locally advanced or metastatic breast cancer. Olivera-Salguero R, Segui E, Cejalvo J, Oliveira M, Tolosa P, Vidal M, Malumbres M, Gavila J, Saura C, Pernas S, Lopez R, Margeli M, Balmana J, Munoz M, Blancas I, Boni V, Ciruelos E, Galve E, Perello A, Sanchez-Bayona R, de la Cruz S, de la Hoya M, Galvan P, Sanfeliu E, Gonzalez-Farre B, Sirenko V, Blanch-Torras A, Canes J, Masanas H, Olmos R, Forns M, Prat A, Casas A, Pascual T. Frontiers in Oncology. 2023 Apr 28;13:1151496. doi: 10.3389/fonc.2023.1151496. PMID: 37188177

In the Literature: january 2023. Martin-Arana J, Gambardella V, Tarazona N, Cejalvo JM, Cervantes A. ESMO Open. 2023 Jan 3;8(1):100763. doi: 10.1016/j.esmoop.2022.100763. PMID: 36603523

In the literature: May 2023. Gambardella V, Cejalvo J, Cervantes A. ESMO Open. 2023 May 15;8(3):101562. doi: 10.1016/j.esmoop.2023.101562. PMID: 37196398

miR-146a-5p promotes angiogenesis and confers trastuzumab resistance in HER2+ breast cancer. Cabello P, Torres-Ruiz S, Adam-Artigues A, Fores-Martos J, Martinez M, Hernando C, Zazo S, Madoz-Gurpide J, Rovira A, Burgues O, Rojo F, Albanell J, Lluch A, Bermejo B, Cejalvo J, Eroles P. Cancers. 2023 Apr 4;15(7):2138. doi: 10.3390/cancers15072138. PMID: 37046799

Nodal positivity and systemic therapy among patients with clinical T1-T2N0 human epidermal growth factor receptor-positive breast cancer: Results from two international cohorts. Weiss A, Martinez-Saez O, Waks A, Laws A, McGrath M, Tarantino P, Portnow L, Winer E, Rey M, Tapia M, Prat A, Partridge A, Tolaney S, Cejalvo J, Mittendorf E, King T. Cancer. 2023 Jun 15;129(12):1836-1845. doi: 10.1002/cncr.34750. PMID: 36951169

Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negativeearly breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study. Oliveira M, Falato C, Cejalvo J, Vila M, Tolosa P, Salvador-Bofill F, Cruz J, Arumi M, Luna A, Guerra J, Vidal M, Martinez-Saez O, Pare L, Gonzalez-Farre B, Sanfeliu E, Ciruelos E, Espinosa-Bravo M, Pernas S, Izarzugaza Y, Esker S, Fan P, Parul P, Santhanagopal A, Sellami D, Villacampa G, Ferrero-Cafiero J, Pascual T, Prat A. Annals of Oncology. 2023 Aug;34(8):670-680. doi: 10.1016/j.annonc.2023.05.004. PMID: 37211044

Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH Trial. Perez-Garcia J, Batista M, Cortez P, Ruiz-Borrego M, Cejalvo J, de la Haba-Rodriguez J, Garrigos L, Racca F, Servitja S, Blanch S, Gion M, Nave M, Fernandez-Abad M, Martinez-Bueno A, Llombart-Cussac A, Sampayo-Cordero M, Malfettone A, Cortes J, Braga S. Neuro-Oncology. 2023 Jan 5;25(1):157-166. doi: 10.1093/neuonc/noac144. PMID: 35639825

Triple negative PAM50 non-basal breast cancer subtype predicts benefit from extended adjuvant capecitabine. Asleh K, Lluch A, Goytain A, Barrios C, Wang X, Torrecillas L, Gao D, Ruiz-Borrego M, Leung S, Bines J, Guerrero-Zotano A, Garcia-Saenz J, Cejalvo J, Herranz J, Torres R, de la Haba-Rodriguez J, Ayala F, Gomez H, Rojo F, Nielsen T, Martin M. Clinical Cancer Research. 2023 Jan 17;29(2):389-400. doi: 10.1158/1078-0432.CCR-22-2191. PMID: 36346687

Immunological landscape of HER-2 positive breast cancer. Moragon S, Hernando C, Martinez-Martinez M, Tapia M, Ortega-Morillo B, Lluch A, Bermejo B, Cejalvo J. Cancers. 2022 Jun 28;14(13):3167. doi: 10.3390/cancers14133167. PMID: 35804943

In the literature: February 2022. Gambardella V, Cejalvo JM, Gonzalez Barrallo I, Gimeno Valiente F, Cervantes A. ESMO open. 2022 Feb 23;7(2):100411. doi: 10.1016/j.esmoop.2022.100411. PMID: 35219243

In the literature: November 2022. Gambardella V, Cejalvo J, Cervantes A. ESMO Open. 2022 Nov 17;7(6):100643. doi: 10.1016/j.esmoop.2022.100643. PMID: 36403559

LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer. Perez-Nunez I, Rozalen C, Palomeque J, Sangrador I, Dalmau M, Comerma L, Hernandez-Prat A, Casadevall D, Menendez S, Liu D, Shen M, Berenguer J, Ruiz I, Pena R, Montanes J, Alba M, Bonnin S, Ponomarenko J, Gomis R, Cejalvo J, Servitja S, Marzese D, Morey L, Voorwerk L, Arribas J, Bermejo B, Kok M, Pusztai L, Kang Y, Albanell J, Celia-Terrassa T. Nature Cancer. 2022 Mar;3(3):355-370. doi: 10.1038/s43018-022-00339-4. PMID: 35301507

miR-99a-5p modulates doxorubicin resistance via the COX-2/ABCG2 axis in triple-negative breast cancer: from the discovery to in vivo studies. Garrido-Cano I, Adam-Artigues A, Lameirinhas A, Blandez J, Candela-Noguera V, Rojo F, Zazo S, Madoz-Gurpide J, Lluch A, Bermejo B, Sancenon F, Cejalvo J, Martinez-Manez R, Eroles P. Cancer Communications. 2022 Dec;42(12):1412-1416. doi: 10.1002/cac2.12352. PMID: 35997029

mTOR inhibition and trastuzumab-emtansine (T-DM1) in HER2-positive breast cancer. Casadevall D, Hernandez-Prat A, Garc A-Alonso S, Arpi-Llucia O, Menendez S, Qin M, Guardia C, Morancho B, Sanchez-Mart N F, Zazo S, Gavilan E, Sabbaghi M, Eroles P, Cejalvo J, Lluch A, Rojo F, Pandiella A, Rovira A, Albanell J. Molecular Cancer Research. 2022 Jul 6;20(7):1108-1121. doi: 10.1158/1541-7786.MCR-21-0545. PMID: 35348729

Oncolytic viruses: a new immunotherapeutic approach for breast cancer treatment?. Cejalvo JM, Falato C, Villanueva L, Tolosa P, Gonzalez X, Pascal M, Canes J, Gavila J, Manso L, Pascual T, Prat A, Salvador F. Cancer Treatment Reviews. 2022 May;106:102392. doi: 10.1016/j.ctrv.2022.102392. PMID: 35436729

Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A. Mouron S, Bueno MJ, Lluch A, Manso L, Calvo I, Cortes J, Garcia-Saenz JA, Gil-Gil M, Martinez-Janez N, Apala JV, Caleiras E, Ximénez-Embún P, Muñoz J, Gonzalez-Cortijo L, Murillo R, Sánchez-Bayona R, Cejalvo JM, Gómez-López G, Fustero-Torre C, Sabroso-Lasa S, Malats N, Martinez M, Moreno A, Megias D, Malumbres M, Colomer R, Quintela-Fandino M. Nature Communications. 2022 Dec 7;13(1):7529. doi: 10.1038/s41467-022-35065-z. PMID: 36477027

SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of PD1 mRNA. Prat A, Paz-Ares L, Juan M, Felip E, Garralda E, Gonzalez B, Arance A, Martin-Liberal J, Gavila J, Lopez-Gonzalez A, Miguel Cejalvo J, Izarzugaza Y, Amillano K, Garcia Corbacho J, Saura C, Racca F, Hierro C, Sanfeliu E, Gonzalez X, Canes J, Villacampa G, Salvador F, Pascual T, Mesia R, Cervantes A, Tabernero J. Future Oncology. 2022 Oct 6. doi: 10.2217/fon-2022-0660. PMID: 36200668

Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer. Adam-Artigues A, Arenas E, Martinez-Sabadell A, Braso-Maristany F, Cervera R, Tormo E, Hernando C, Martinez M, Carbonell-Asins J, Simon S, Poveda J, Moragon S, Zazo S, Martinez D, Rovira A, Burgues O, Rojo F, Albanell J, Bermejo B, Lluch A, Prat A, Arribas J, Eroles P, Cejalvo J. Science Advances. 2022 May 20;8(20):eabk2746. doi: 10.1126/sciadv.abk2746. PMID: 35594351

Circulating miR-30b-5p levels in plasma as a novel potential biomarker for early detection of breast cancer. Adam-Artigues A, Garrido-Cano I, Simon S, Ortega B, Moragon S, Lameirinhas A, Constancio V, Salta S, Burgues O, Bermejo B, Henrique R, Lluch A, Jeronimo C, Eroles P, Cejalvo J. ESMO Open. 2021 Jan 18;6(1):100039. doi: 10.1016/j.esmoop.2020.100039. PMID: 33477007

Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. Schettini F, Chic N, Braso-Maristany F, Pare L, Pascual T, Conte B, Martinez-Saez O, Adamo B, Vidal M, Barnadas E, Fernandez-Martinez A, Gonzalez-Farre B, Sanfeliu E, Cejalvo J, Perrone G, Sabarese G, Zalfa F, Peg V, Fasani R, Villagrasa P, Gavila J, Barrios C, Lluch A, Martin M, Locci M, De Placido S, Prat A. NPJ Breast Cancer. 2021 Jan 4;7(1):1. doi: 10.1038/s41523-020-00208-2. PMID: 33397968

Fertility and breast cancer: a literature review of counseling, preservation options and outcomes. Moragon S, Di Liello R, Bermejo B, Hernando C, Olcina E, Chirivella I, Lluch A, Cejalvo JM, Martinez MT, Critical Reviews In Oncology/Hematology. 2021 Aug 27;166:103461. doi: 10.1016/j.critrevonc.2021.103461. PMID: 34461268

First nationwide molecular screening program in Spain for patients with advanced breast cancer: results from the AGATA SOLTI-1301 Study. Pernas S, Villagrasa P, Vivancos A, Scaltriti M, Rodon J, Burgues O, Nuciforo P, Canes J, Pare L, Duenas M, Vidal M, Cejalvo J, Perello A, Llommbard-Cussac A, Dorca J, Montano A, Pascual T, Oliveira M, Ribas G, Rapado I, Prat A, Ciruelos E. Frontiers in Oncology. 2021 Nov 4;11:744112. doi: 10.3389/fonc.2021.744112. PMID: 34804931

In the literature: April 2021. Martin-Martorell P, Gonzalez-Barrallo I, Gambardella V, Cejalvo J M, Cervantes A. ESMO open. 2021 Apr 19;6(3):100116. doi: 10.1016/j.esmoop.2021.100116. PMID: 33887688

In the literature: August 2021. Gambardella V, Alfaro-Cervello C, Cejalvo J, Tapia M, Cervantes A. ESMO Open. 2021 Aug 16;6(5):100247. doi: 10.1016/j.esmoop.2021.100247. PMID: 34411970

In the literature: February 2021. Cejalvo J, Gambardella V, Fleitas T, Cervantes A. ESMO Open. 2021 Feb 24;6(2):100061. doi: 10.1016/j.esmoop.2021.100061. PMID: 33639602

In the literature: June 2021. Gambardella V, Candia L, Tapia M, Cejalvo JM, Cervantes A. ESMO open. 2021 Jun;6(3):100186. doi: 10.1016/j.esmoop.2021.100186. PMID: 34098228

Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study. Gambardella V, Lombardi P, Carbonell-Asins JA, Tarazona N, Cejalvo JM, Gonzalez-Barrallo I, Martin-Arana J, Tebar-Martinez R, Viala A, Bruixola G, Hernando C, Blasco I, Papaccio F, Martinez-Ciarpaglini C, Alfaro-Cervello C, Seda-Garcia E, Blesa S, Chirivella I, Castillo J, Monton-Bueno JV, Rosello S, Huerta M, Perez-Fidalgo A, Martin-Martorell P, Insa-Molla A, Fleitas T, Rentero-Garrido P, Zuniga-Trejos S, Cervantes A, Roda D. British Journal of Cancer. 2021 Oct;125(9):1261-1269. doi: 10.1038/s41416-021-01502-x. PMID: 34493820

Nanoporous Anodic Alumina-Based Sensor for miR-99a-5p Detection as an Effective Early Breast Cancer Diagnostic Tool. Garrido-Cano I, Pla L, Santiago-Felipe S, Simon S, Ortega B, Bermejo B, Lluch A, Cejalvo J, Eroles P, Martinez-Manez R. ACS Sensors. 2021 Mar 26;6(3):1022-1029. doi: 10.1021/acssensors.0c02222. PMID: 33599490

Oral Selective Estrogen Receptor Degraders (SERDs) as a novel breast cancer therapy: present and future from a clinical perspective. Hernando C, Ortega-Morillo B, Tapia M, Moragon S, Martinez M, Eroles P, Garrido-Cano I, Adam-Artigues A, Lluch A, Bermejo B, Cejalvo J. International Journal of Molecular Sciences. 2021 Jul 22;22(15):7812. doi: 10.3390/ijms22157812. PMID: 34360578

SOLTI-1805 TOT-HER3 study concept: a window-of-opportunity trial of patritumab deruxtecan, a her3 directed antibody drug conjugate, in patients with early breast cancer. Pascual T, Oliveira M, Ciruelos E, Ezquerra M, Saura C, Gavila J, Pernas S, Munoz M, Vidal M, Vila M, Cejalvo J, Gonzalez-Farre B, Espinosa-Bravo M, Cruz J, Salvador-Bofill F, Guerra J, Barrera A, de Dios M, Esker S, Fan P, Martinez-Saez O, Villacampa G, Pare L, Ferrero-Cafiero J, Villagrasa P, Prat A. Frontiers in Oncology. 2021 Apr 23;11:638482. doi: 10.3389/fonc.2021.638482. PMID: 33968735

+ Info
Title: Involvement of EZH2-MYC loop and SALL4 in epithelial-mesenchymal transition (EMT) and trastuzumab resistance process in HER2+ breast cancer
Doctoral candidate: Pattanayak Pattanayak, Chaudhuri Birlipta
Director(s): Eroles Asensio, Pilar; Cejalvo Andújar, Juan Miguel
Date of the defense: 26/02/2021
University: Universitat de València

Title: Uncovering the molecular and cellular mechanisms of metastatic dormancy in luminal breast cancer
Doctoral candidate: Cejalvo Andújar, Juan Miguel
Director(s): Gomis Cabré, Roger; Prat Aparicio, Aleix; Palacín Prieto, Manuel
Date of the defense: 22/01/2020
University: University de Barcelona